[go: up one dir, main page]

BRPI1011226A2 - métodos para tratar condições relacionadas ao cabelo - Google Patents

métodos para tratar condições relacionadas ao cabelo

Info

Publication number
BRPI1011226A2
BRPI1011226A2 BRPI1011226A BRPI1011226A BRPI1011226A2 BR PI1011226 A2 BRPI1011226 A2 BR PI1011226A2 BR PI1011226 A BRPI1011226 A BR PI1011226A BR PI1011226 A BRPI1011226 A BR PI1011226A BR PI1011226 A2 BRPI1011226 A2 BR PI1011226A2
Authority
BR
Brazil
Prior art keywords
methods
related conditions
treat hair
hair related
treat
Prior art date
Application number
BRPI1011226A
Other languages
English (en)
Inventor
Francesca Viti
Salvatore Bellinvia
Sergio Baroni
Original Assignee
Giuliani Internac Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Internac Ltd filed Critical Giuliani Internac Ltd
Publication of BRPI1011226A2 publication Critical patent/BRPI1011226A2/pt
Publication of BRPI1011226B1 publication Critical patent/BRPI1011226B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
BRPI1011226-0A 2009-02-16 2010-02-16 uso de uma composição farmacêutica para tratar condições relacionadas ao cabelo BRPI1011226B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US28746109P 2009-12-17 2009-12-17
PCT/EP2010/000939 WO2010091894A2 (en) 2009-02-16 2010-02-16 Methods of treating hair related conditions

Publications (2)

Publication Number Publication Date
BRPI1011226A2 true BRPI1011226A2 (pt) 2016-03-15
BRPI1011226B1 BRPI1011226B1 (pt) 2019-10-29

Family

ID=42562114

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1011226-0A BRPI1011226B1 (pt) 2009-02-16 2010-02-16 uso de uma composição farmacêutica para tratar condições relacionadas ao cabelo
BRPI1008752-4A BRPI1008752B1 (pt) 2009-02-16 2010-02-16 Compostos alquilamido, composições farmacêuticas e usos dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI1008752-4A BRPI1008752B1 (pt) 2009-02-16 2010-02-16 Compostos alquilamido, composições farmacêuticas e usos dos mesmos

Country Status (25)

Country Link
US (11) US8754127B2 (pt)
EP (4) EP2396081B1 (pt)
JP (4) JP5715070B2 (pt)
KR (2) KR101776337B1 (pt)
CN (3) CN102316931B (pt)
AR (1) AR080596A1 (pt)
AU (2) AU2010213093B2 (pt)
BR (2) BRPI1011226B1 (pt)
CA (2) CA2752626C (pt)
CY (2) CY1119225T1 (pt)
DK (2) DK2805746T3 (pt)
EA (2) EA020198B1 (pt)
ES (3) ES2429143T3 (pt)
HR (2) HRP20170936T1 (pt)
HU (2) HUE050267T2 (pt)
IL (2) IL214665A (pt)
LT (2) LT2396081T (pt)
MX (3) MX381002B (pt)
NZ (2) NZ595080A (pt)
PL (1) PL2396081T3 (pt)
PT (3) PT2396081T (pt)
SI (2) SI2805746T1 (pt)
UA (2) UA105037C2 (pt)
WO (2) WO2010091892A2 (pt)
ZA (1) ZA201106256B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4805556A (en) 1988-01-15 1989-02-21 Union Carbide Corporation Reactor system and method for forming uniformly large-diameter polycrystalline rods by the pyrolysis of silane
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
SI2805746T1 (sl) * 2009-02-16 2020-10-30 Nogra Pharma Limited Alkilamido spojine in njihova uporaba
EP3320902B1 (en) 2011-03-07 2021-02-17 Amgen (Europe) GmbH Methods for treating diseases using isoindoline compounds
EP2811993B1 (en) * 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (es) 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
EP2897603A1 (en) * 2012-09-13 2015-07-29 Nogra Pharma Limited Methods of inhibiting hair growth
ES2675169T3 (es) * 2012-09-13 2018-07-09 Nogra Pharma Limited Procedimientos de tratamiento de las afecciones relacionadas con el cabello
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
CN107613971A (zh) 2015-04-06 2018-01-19 宾夕法尼亚大学董事会 用于减少、或预防或逆转哺乳动物对象中皮肤色素沉着增加的组合物和方法
US20190216893A1 (en) * 2016-06-03 2019-07-18 The Scripps Research Institute Compositions and methods of modulating immune response
US20220000818A1 (en) * 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
PT3921299T (pt) * 2019-02-08 2025-02-17 Nogra Pharma Ltd Processo de fabrico do ácido 3-(4'-aminofenil)-2- metoxipropiónico, bem como dos seus análogos e intermediários
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
NZ224087A (en) 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
ATE113209T1 (de) 1988-05-05 1994-11-15 Tillotts Pharma Ag Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
ATE256468T1 (de) 1990-10-22 2004-01-15 Gastro Services Pty Ltd Behandlung von nicht-entzündlichen darmerkrankungen
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
DE69331414T2 (de) 1992-03-17 2002-08-08 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide, herstellung und anwendung
ATE214608T1 (de) 1992-06-30 2002-04-15 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) 1994-05-11 1995-11-23 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996030016A2 (en) 1995-03-28 1996-10-03 Janssen Pharmaceutica N.V. Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
WO1999015520A1 (en) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Fused or nonfused benzene compounds
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
DE60013491T2 (de) 2000-04-19 2005-09-01 Neurotech Co., Ltd., Suwon Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
CA2410647C (en) * 2000-05-29 2010-02-09 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropanoic acid derivatives
ES2333337T3 (es) 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
WO2002046161A1 (en) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
EP1389044A4 (en) 2001-04-18 2006-07-05 Merck & Co Inc PPAR ALPHA GAMMA LIGANDS OR AGONISTS FOR THE TREATMENT OF INFLAMMATION
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
IL161429A0 (en) 2001-10-16 2004-09-27 Reddys Lab Ltd Dr Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
WO2003043569A2 (en) 2001-11-16 2003-05-30 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20060013775A1 (en) 2001-11-26 2006-01-19 Gristwood Robert W Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
WO2003093498A1 (en) 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
JP5198768B2 (ja) 2003-07-21 2013-05-15 メルク セローノ ソシエテ アノニム アルキニルアリールカルボキサミド
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US20070093476A1 (en) 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
GT200500246A (es) 2004-09-09 2006-04-17 Combinacion de compuestos organicos
WO2006037052A2 (en) 2004-09-27 2006-04-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Modulating mxa expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
SI2805746T1 (sl) 2009-02-16 2020-10-30 Nogra Pharma Limited Alkilamido spojine in njihova uporaba
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2013012662A2 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
US9491942B2 (en) 2011-10-17 2016-11-15 The Regents Of The University Of California Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods
ES2602075T3 (es) 2011-10-31 2017-02-17 Larsen, Claus Selch Profármacos de agentes antiinflamatorios no esteroideos (AINE)
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (es) 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
WO2013168438A1 (ja) 2012-05-10 2013-11-14 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US20150126553A1 (en) 2012-06-01 2015-05-07 Nogra Pharma Limited Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2861580B1 (en) 2012-06-07 2018-04-25 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
EP2897603A1 (en) 2012-09-13 2015-07-29 Nogra Pharma Limited Methods of inhibiting hair growth
ES2675169T3 (es) 2012-09-13 2018-07-09 Nogra Pharma Limited Procedimientos de tratamiento de las afecciones relacionadas con el cabello
HUE030707T2 (en) 2013-03-26 2017-05-29 Lipid Therapeutics Gmbh Pharmaceutical composition containing phosphatidylcholine for the treatment of ulcerative colon inflammation
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
WO2016154730A1 (en) 2015-04-02 2016-10-06 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
RU2745065C2 (ru) 2015-06-15 2021-03-18 ЭнЭмДи ФАРМА A/C Соединения для применения для лечения нервно-мышечных расстройств
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
EP3419616A1 (en) 2016-02-26 2019-01-02 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
AU2010213095A1 (en) 2011-09-08
NZ595076A (en) 2013-09-27
IL214664A (en) 2015-09-24
CN104666288B (zh) 2017-08-04
SI2805746T1 (sl) 2020-10-30
PL2396081T3 (pl) 2017-10-31
ES2630044T3 (es) 2017-08-17
EP2396082A2 (en) 2011-12-21
EA020198B1 (ru) 2014-09-30
CN102316932B (zh) 2014-07-09
JP2012517969A (ja) 2012-08-09
EP2396081A2 (en) 2011-12-21
EP2805746A1 (en) 2014-11-26
CA2752626C (en) 2018-03-27
CY1123213T1 (el) 2021-12-31
US9901557B2 (en) 2018-02-27
EP2396081B1 (en) 2017-04-05
MX381002B (es) 2025-03-12
CN104666288A (zh) 2015-06-03
CY1119225T1 (el) 2018-02-14
US20200188340A1 (en) 2020-06-18
CA2752623A1 (en) 2010-08-19
AU2010213095B2 (en) 2015-09-17
BRPI1008752A2 (pt) 2016-03-08
DK2396081T3 (en) 2017-07-10
UA105037C2 (uk) 2014-04-10
CN102316932A (zh) 2012-01-11
WO2010091892A3 (en) 2010-10-21
NZ595080A (en) 2013-09-27
AU2010213093B2 (en) 2016-01-07
HRP20170936T1 (hr) 2017-09-22
EP2805746B1 (en) 2020-05-06
US20170172956A1 (en) 2017-06-22
MX2011008602A (es) 2011-09-09
CN102316931A (zh) 2012-01-11
HUE032999T2 (hu) 2017-11-28
HRP20201184T1 (hr) 2020-12-11
BRPI1008752B1 (pt) 2020-02-11
JP2012517968A (ja) 2012-08-09
ZA201106256B (en) 2012-05-30
US20180369178A1 (en) 2018-12-27
HUE050267T2 (hu) 2020-11-30
US20190269637A1 (en) 2019-09-05
JP2015155427A (ja) 2015-08-27
JP2014237692A (ja) 2014-12-18
WO2010091894A2 (en) 2010-08-19
JP5715070B2 (ja) 2015-05-07
MX2011008601A (es) 2011-09-09
ES2806691T3 (es) 2021-02-18
AR080596A1 (es) 2012-04-25
US10398667B2 (en) 2019-09-03
US20220354809A1 (en) 2022-11-10
KR101800901B1 (ko) 2017-11-23
EA201171062A1 (ru) 2012-01-30
UA109525C2 (xx) 2015-09-10
KR20110120945A (ko) 2011-11-04
EP3744398A1 (en) 2020-12-02
AU2010213093A1 (en) 2011-09-08
KR101776337B1 (ko) 2017-09-07
US8796334B2 (en) 2014-08-05
LT2805746T (lt) 2020-09-25
IL214664A0 (en) 2011-09-27
IL214665A0 (en) 2011-09-27
US10959970B2 (en) 2021-03-30
PT2396081T (pt) 2017-07-11
EP2396082B1 (en) 2013-07-31
US20120053245A1 (en) 2012-03-01
US8754127B2 (en) 2014-06-17
EA201171063A1 (ru) 2012-01-30
US20160338927A1 (en) 2016-11-24
PT2396082E (pt) 2013-10-03
EA020856B1 (ru) 2015-02-27
JP5820030B2 (ja) 2015-11-24
CA2752626A1 (en) 2010-08-19
CA2752623C (en) 2017-07-04
US20150148418A1 (en) 2015-05-28
WO2010091894A3 (en) 2010-11-11
US9511041B2 (en) 2016-12-06
IL214665A (en) 2017-02-28
JP5645851B2 (ja) 2014-12-24
ES2429143T3 (es) 2013-11-13
PT2805746T (pt) 2020-08-17
WO2010091892A2 (en) 2010-08-19
US20120053244A1 (en) 2012-03-01
BRPI1011226B1 (pt) 2019-10-29
LT2396081T (lt) 2017-09-11
DK2805746T3 (da) 2020-08-10
SI2396081T1 (sl) 2017-09-29
CN102316931B (zh) 2014-11-19
US20150051285A1 (en) 2015-02-19
US20200383942A1 (en) 2020-12-10
US10137101B2 (en) 2018-11-27
KR20110120946A (ko) 2011-11-04

Similar Documents

Publication Publication Date Title
BRPI1011226A2 (pt) métodos para tratar condições relacionadas ao cabelo
BRPI0915476A2 (pt) dispositivo para tratar problemas respiratórios
FI20095291L (fi) Kuitujen käsittely muovausta kestäväksi
BR112014006324A2 (pt) método para tratar hcv
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
PT2499249T (pt) Moléculas antisentido e métodos para tratar patologias
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1008253A2 (pt) Metoso para tratar biomassa
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga
BR112012002269A2 (pt) implemento para tratar superfície
BRPI0923967A2 (pt) cosmético para os cabelos
BRPI0919127A2 (pt) métodos para tratamento de água
BR112012014032A2 (pt) dispositivo para aparar cabelo
BR112013008528A2 (pt) métodos para tratar psoríase
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BR112014009785A2 (pt) método para tratar ou reduzir efp
BRPI1013183A2 (pt) cosmético para o cabelo
BRPI0822264A2 (pt) Dapsona para tratar rosácea
DK2453858T3 (da) Fremgangsmåde
BRPI0921679A2 (pt) composto útil para tratar celulite
BR112013002697A2 (pt) método para estimular o crescimento do cabelo
BR112014005614A2 (pt) método para produzir chocolate, e, chocolate
BR112012022525A2 (pt) método para produzir butanol
BR112012019786A2 (pt) processo para prevenir ou atenuar bioincrustação

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GIULIANI INTERNACIONAL LIMITED (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOGRA PHARMA LIMITED (IE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2710 DE 13-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.